Loading...
•
Jun 30, 2022
Collegium Q2 2022 Earnings Report
Collegium reported record revenue and completed the BDSI integration
Key Takeaways
Collegium Pharmaceutical reported record net revenue of $123.5 million for the second quarter of 2022. The company completed the BDSI integration and is on track to exceed targeted run rate synergies of at least $75 million. Full year Adjusted EBITDA guidance was also raised.
Generated record net revenue of $123.5 million.
Completed BDSI Integration; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million.
Raised Full Year Adjusted EBITDA Guidance.
Increased Collegium’s market share of the Branded ER market to 49.0% in June 2022.
Forward Guidance
The Company updates its full-year 2022 guidance for Total Adjusted Operating Expenses and Total Adjusted EBITDA:
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...